Cargando…

Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug–Drug Interaction with Antidepressants

Tamoxifen is an estrogen receptor antagonist used in the treatment of breast cancer. It is a prodrug that is converted by several cytochrome P450 enzymes to a primary metabolite, N-desmethyltamoxifen (NDT), which is then further modified by CYP2D6 to a pharmacologically potent secondary metabolite,...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacLeod, A. Kenneth, McLaughlin, Lesley A., Henderson, Colin J., Wolf, C. Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society for Pharmacology and Experimental Therapeutics 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193068/ https://www.ncbi.nlm.nih.gov/pubmed/27756789 http://dx.doi.org/10.1124/dmd.116.073437

Ejemplares similares

HDAC Inhibitors Increase NRF2-Signaling in Tumour Cells and Blunt the Efficacy of Co-Adminstered Cytotoxic Agents
por: McMahon, Michael, et al.
Publicado: (2014)

A Targeted in Vivo SILAC Approach for Quantification of Drug Metabolism Enzymes: Regulation by the Constitutive Androstane Receptor
por: MacLeod, A. Kenneth, et al.
Publicado: (2013)

An Enhanced In Vivo Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) Model for Quantification of Drug Metabolism Enzymes
por: MacLeod, A. Kenneth, et al.
Publicado: (2015)

Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability
por: Henderson, Colin J., et al.
Publicado: (2015)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice
por: Kapelyukh, Y., et al.
Publicado: (2019)

Pre-clinical evaluation of CYP 2D6 dependent drug–drug interactions between primaquine and SSRI/SNRI antidepressants
por: Jin, Xiannu, et al.
Publicado: (2016)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)

THE INHIBITION OF THE BACTERIOSTATIC ACTION OF SULFONAMIDE DRUGS BY SUBSTANCES OF ANIMAL AND BACTERIAL ORIGIN
por: MacLeod, Colin M.
Publicado: (1940)

The ethics of CYP2D6 testing for patients considering tamoxifen
por: Hartman, Anne-Renee, et al.
Publicado: (2007)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials
por: Henderson, C.J., et al.
Publicado: (2019)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
por: Li, Jingmei, et al.
Publicado: (2013)

Which antidepressant agent can be used in patients receiving tamoxifen?
por: Maamri, A., et al.
Publicado: (2021)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

Cytochrome b(5) null mouse: a new model for studying inherited skin disorders and the role of unsaturated fatty acids in normal homeostasis
por: Finn, Robert D., et al.
Publicado: (2010)

Improving the predictive power of xenograft and syngeneic anti-tumour studies using mice humanised for pathways of drug metabolism
por: Henderson, Colin J., et al.
Publicado: (2023)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
por: Brooks, Jennifer D., et al.
Publicado: (2018)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

Insights into CYP2B6-mediated drug–drug interactions
por: Hedrich, William D., et al.
Publicado: (2016)

Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway
por: Gedde-Dahl, Ane, et al.
Publicado: (2022)

Tamoxifen: the drug that came in from the cold
por: Hughes-Davies, L, et al.
Publicado: (2009)

The Underrated Risks of Tamoxifen Drug Interactions
por: Hansten, Philip D.
Publicado: (2018)

Vulnerability, Risk and Harm for People Who Use Drugs and Are Engaged in Transactional Sex: Learning for Service Delivery
por: Matheson, Catriona, et al.
Publicado: (2022)

Vitamin B6 Antidepressant Effects Are Comparable to Common Antidepressant Drugs in Bacillus-Calmette-Guerin Induced Depression Model in Mice
por: Mesripour, Azadeh, et al.
Publicado: (2022)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response
por: Wegman, Pia P, et al.
Publicado: (2005)

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2020)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
por: Lammers, L A, et al.
Publicado: (2010)

Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice
por: Szopa, Aleksandra, et al.
Publicado: (2015)

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset
por: Damkier, Per, et al.
Publicado: (2017)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

Key Challenges in the Search for Innovative Drug Treatments for Special Populations. Converging Needs in Neonatology, Pediatrics, and Medical Genetics
por: MacLeod, Stuart
Publicado: (2017)

Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice
por: McMillan, JoEllyn M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cqv15jii933dpuk04935qqn2mo